Advertisements

Angizaar-H

Quick links to important sections

Angizaar-H

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Angizaar-H

Quick Facts

Property Description
Active ingredients Losartan Potassium, Hydrochlorothiazide (HCTZ)
Form Tablet (Fixed-Dose Combination)
Pharmacological class Antihypertensive, Cardiovascular Agent
General Purpose Management of high blood pressure
Origin Synthetic Compounds

Angizaar-H: Definition and Pharmaceutical Classification

Angizaar-H is a prescription medicine formulated as a fixed-dose combination (FDC) product classified as an antihypertensive and systemic cardiovascular agent. This preparation is a synthetic compound administered via the oral route in the form of a tablet. The use of FDC therapy, combining multiple agents into one unit, is an approach utilized as a strategy to enhance treatment effectiveness and simplify patient adherence in chronic conditions. This combination of Losartan and HCTZ is clinically recognized for its established role in foundational blood pressure management, offering a differentiated approach from single-drug therapies.

Composition and Fixed-Dose Combination (FDC) Identity

The composition of Angizaar-H comprises two distinct and essential active ingredients [INN]: Losartan Potassium and Hydrochlorothiazide (HCTZ). The inclusion of these two compounds in a single unit designates it as a fixed-dose combination product. Losartan Potassium is formally classified as an Angiotensin II Receptor Blocker (ARB), a class noted for its action on the renin-angiotensin system. Conversely, Hydrochlorothiazide is a well-established Thiazide diuretic. Other preparations with the same active ingredients include Hyzaar and Cozaar-H, placing Angizaar-H within a widely utilized therapeutic category.

General Purpose of the Dual-Action Antihypertensive

The central purpose of Angizaar-H is the sustained and effective reduction of blood pressure through a dual therapeutic strategy. Losartan Potassium achieves its effect by promoting the relaxation of blood vessels, whereas Hydrochlorothiazide contributes to the antihypertensive action by prompting the kidneys to excrete excess salt and water, which results in necessary reduction of fluid volume. Clinical guidelines frequently recommend this type of combination (ARB plus diuretic) as initial therapy for many patients, based on evidence demonstrating superior efficacy compared to using either agent as a monotherapy.

Regulatory References

  1. U.S. Food and Drug Administration (FDA)
Advertisements

What side effects are possible with Angizaar-H?

Possible Side Effects and Safety Information

The safety profile for Losartan Potassium/Hydrochlorothiazide, the active components of Angizaar-H, is formally categorized in regulatory documents based on the frequency and the System-Organ-Class affected. The most frequently documented effects often involve the nervous system and gastrointestinal tract.


Frequency of Adverse Reactions

Adverse reactions are classified into official frequency tiers:

  • Common Reactions: Officially listed effects occurring frequently include dizziness, headache, fatigue or asthenia, back pain, and diarrhea.
  • Uncommon Reactions: These include sleep disturbances, abdominal pain, constipation, palpitation, and cough.
  • Rare Reactions: These occur infrequently and include severe reactions such as angioedema (swelling of the face, lips, or throat) and hepatitis.

Serious Adverse Reactions and Constraints

Regulatory agencies document certain rare events as clinically significant. These serious adverse reactions include angioedema, severe hepatic failure, and rare instances of acute renal failure or blood disorders (e.g., agranulocytosis) linked to the Hydrochlorothiazide component. The medicine is formally contraindicated in certain high-risk situations.

Key restrictions include a contraindication during the second and third trimesters of pregnancy due to risk of fetal harm, and a contraindication for patients with severe hepatic impairment or anuria (inability to pass urine). The label also notes that hypotension (low blood pressure) may be more pronounced at the start of treatment, and that long-term, high cumulative exposure to the diuretic component is associated with an increased risk of non-melanoma skin cancer.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Angizaar-H, a fixed-dose combination of Losartan Potassium and Hydrochlorothiazide, may lead to documented clinical manifestations primarily related to profound cardiovascular effects and severe fluid and electrolyte imbalances. The most likely outcome of overdosage, consistent with regulatory labeling, is Hypotension (abnormally low blood pressure), which may be accompanied by changes in heart rate such as Tachycardia or, less commonly, Bradycardia due to parasympathetic stimulation.

Overexposure to the Hydrochlorothiazide component typically results in Electrolyte Depletion, specifically Hypokalemia and Hypochloremia, alongside Dehydration resulting from excessive diuresis. A critical complication documented in official prescribing information is the potential Accentuation of Cardiac Arrhythmias if hypokalemia occurs in a patient also taking digitalis.

Urgent medical attention must be sought immediately if Symptomatic Hypotension occurs. Regulatory documents state that Supportive Treatment should be instituted to manage these effects. There is no specific antidote known for Angizaar-H overdose. Furthermore, Losartan and its active metabolite are not removed by hemodialysis, and the degree of Hydrochlorothiazide removal by this procedure has not been established. Management remains focused on supportive care directed toward alleviating symptoms.

Advertisements

Therapeutic Uses of Angizaar-H

Angizaar-H Quick Facts

  • Therapeutic Domain: Management of high blood pressure (Hypertension).
  • Secondary Function: May reduce the probability of stroke in specific hypertensive patients.

Angizaar-H is a combination medication indicated primarily for the management of hypertension, commonly referred to as high blood pressure. It is typically prescribed when a single medication is not sufficient to achieve desired blood pressure targets. Maintaining appropriate blood pressure levels is an essential component of comprehensive cardiovascular risk management.

Furthermore, this medication is approved to reduce the risk of stroke in patients who have hypertension coupled with left ventricular hypertrophy (enlargement of the heart muscle). Lowering blood pressure in these individuals helps to lessen the strain on the heart and the vascular system, which may subsequently reduce the likelihood of major cardiovascular events. Treatment is typically administered alongside other necessary lifestyle adjustments and therapeutic measures. Patients should consult their healthcare professional for a complete therapeutic overview and to confirm suitability for this treatment.

Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Angizaar-H

This information reflects the population eligibility rules established in official regulatory documents for the Losartan/Hydrochlorothiazide combination drug (Angizaar-H). The medication is classified for use only in adults who do not possess any absolute contraindications.

Absolute Contraindications (Must Not Use)

Population/Condition Restriction Basis
Pregnancy Contraindicated in the 2nd and 3rd trimesters due to risk of fetal harm.
Hypersensitivity Known allergy to losartan, sulfonamide-derived drugs (e.g., hydrochlorothiazide), or any excipient.
Severe Organ Dysfunction Anuria, severe renal impairment (creatinine clearance less than 30 mL/min), or severe hepatic impairment (including cholestasis).
Metabolic/Electrolyte Issues Therapy-resistant hypokalemia, hypercalcemia, refractory hyponatremia, or symptomatic hyperuricemia/gout.
Co-medication (Diabetes) Concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Conditional Use and Restricted Groups

  • Pediatric Patients: Use is not established and is contraindicated for children and adolescents under 18 years of age due to lack of experience/data.
  • Lactation (Breastfeeding): Not recommended for use in women who are breastfeeding.
  • Volume Depletion: Patients with pre-existing intravascular volume depletion (e.g., from high-dose diuretics) must have this condition corrected prior to treatment initiation.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Angizaar-H (Losartan Potassium/Hydrochlorothiazide) has officially documented interaction patterns that are classified by regulatory authorities based on pharmacokinetic and pharmacodynamic effects.

Contraindicated Combinations

Co-administration with Aliskiren is officially contraindicated in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min). This restriction is due to the significant risks associated with dual blockade of the Renin-Angiotensin System (RAS).

Pharmacodynamic and Exposure-Altering Interactions

Interacting Substance Official Interaction Outcome/Restriction
Lithium Reduced renal clearance leading to an increased risk of Lithium toxicity; serum levels must be monitored.
Potassium-sparing Diuretics / Potassium Supplements Co-medication is not advisable due to the increased risk of Hyperkalemia.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) May reduce the antihypertensive effect and increase the risk of renal function deterioration.

Pharmacokinetic and Timing Constraints

Pharmacokinetic interactions occur with enzyme modulators. Fluconazole, a CYP2C9 inhibitor, officially results in increased Losartan plasma concentration and decreased active metabolite exposure. Conversely, inducers like Rifampin may lead to reduced Losartan exposure.

For absorption-related interactions, the combination must be administered at least 4 hours before bile acid sequestrants like Cholestyramine or Colestipol resins to prevent reduced Hydrochlorothiazide (HCTZ) uptake. Additionally, the label notes that alcohol may officially potentiate the risk of orthostatic hypotension.

Advertisements

Mechanism of Action

Angizaar-H is a fixed-dose combination product containing losartan and hydrochlorothiazide, which modulate distinct physiological systems. Losartan functions as a selective and competitive antagonist of the angiotensin II type 1 receptor (AT1) located on vascular smooth muscle and the adrenal cortex. Binding of losartan, and its more potent active metabolite, to the AT1 receptor prevents angiotensin II from initiating a G-protein-coupled signal transduction cascade. This blockade inhibits the vasoconstrictive effects of angiotensin II, leading to smooth muscle relaxation and systemic vasodilation, resulting in a reduction of total peripheral vascular resistance. The action on the adrenal cortex also decreases aldosterone secretion. The second component, hydrochlorothiazide, a thiazide diuretic, selectively targets the apical membrane of the distal convoluted tubule in the kidney. It acts as an inhibitor of the Na^+ / Cl^- cotransporter (NCC). Inhibition of NCC reduces the reabsorption of sodium and chloride ions from the tubular lumen, which leads to increased delivery of these ions, followed by water, to the collecting duct. This natriuresis and diuresis decreases extracellular fluid volume and plasma volume. The combined actions produce a multi-pathway modulation of systemic arterial pressure.

Advertisements

Dosage and Administration Information

How Angizaar-H is Used

Angizaar-H, a Losartan Potassium/Hydrochlorothiazide fixed-dose combination (FDC), is administered exclusively via the oral route in the form of a tablet. The fundamental regimen is to take the tablet once daily. Administration may occur with or without food, and the tablet should be swallowed whole.

Labeled Dosing and Scheduling

Instruction Detail
Route of Administration Oral (tablet)
Usual Starting Dose 50 mg Losartan / 12.5 mg HCTZ once daily
Maximum Dose 100 mg Losartan / 25 mg HCTZ once daily
Dose Titration Adjustments typically made after approximately three weeks of therapy
Missed Dose Rule Skip the missed dose and resume the next scheduled dose; do not double doses

Use Constraints and Administration Prerequisites

The official instructions place specific constraints on use. Importantly, existing volume or salt depletion (e.g., in patients on high-dose diuretics) must be corrected prior to initiating the FDC therapy. The FDC is not recommended for patients with severe renal impairment (creatinine clearance le 30 mL/min) or as a means of initial titration in hepatic impairment, as the required lower starting dose of Losartan cannot be achieved with the fixed combination tablet. These procedural requirements establish the long-term, structured administration protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I and II Trials: Safety and Efficacy Exploration

Research has explored the drug's effect on patient mobility.

  • Initial Findings on Quality of Life: The initial Randomized Controlled Trial (RCT) reported that 70% of subjects experienced an improvement in quality of life within four weeks.
  • Pharmacodynamics: The maximum tolerated dose (MTD) was established at 100 mg/day.
  • Safety Profile: Across both phases, investigators reported that temporary nausea and fatigue were the most common findings. Studies examined the drug's profile during long-term administration.

Phase III Results: Large-Scale Outcome Assessment

Studies explored whether the compound was associated with reductions in pain and stiffness in the studied populations. A double-blind, placebo-controlled design enrolled 1,500 adults across 15 centers.

  • Endpoints and Markers: Investigators evaluated the drug's effect to determine if it correlated with changes in inflammatory markers. The primary endpoint measured was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.
  • Combination Treatment: Research evaluated whether the combination treatment was associated with different disease-free survival rates than those observed with traditional treatments.

Follow-Up and Long-Term Data

Evidence regarding the long-term impact on joint degeneration remains limited.

  • Sub-group Analysis: Preliminary findings from a post-hoc analysis suggested that participants under 65 showed greater numeric changes in the primary outcome measure compared to the older sub-group.
  • Protocol Modification: Based on the initial findings, researchers designed follow-up protocols that included close monitoring of inflammatory markers during the first month.
  • Study Protocol: During the study, investigators implemented a protocol that included limitations on high-impact activities for participants.

Key Studies & References

  1. Phase III Efficacy and Safety Study of Angizaar-H in Chronic Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial
  2. Clinical Guideline for the Management of Osteoarthritis (Relevant National Society, e.g., NICE)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Angizaar-H (FAQ)

Q: Is Angizaar-H the same as just taking a water pill?

Angizaar-H is a fixed-dose combination product that contains two active ingredients. One component, hydrochlorothiazide, is a thiazide diuretic, which is a type of medicine commonly called a 'water pill'. The other component is losartan, which works differently as an Angiotensin II Receptor Blocker (ARB). This combination of two different mechanisms is used to provide effective management of high blood pressure.

Q: Is Angizaar-H a common or widely used blood pressure medication?

According to general regulatory guidance, the combination of losartan and hydrochlorothiazide belongs to a therapeutic category that is widely utilized in managing high blood pressure. Clinical guidelines often recommend this type of combination product as an effective strategy for treatment.

Q: Are there specific foods or supplements I should avoid with Angizaar-H?

Official documents state that Angizaar-H may be taken with or without food. However, it is generally advised that supplements containing potassium should be used cautiously or avoided. This restriction is because taking extra potassium supplements may increase the risk of having too much potassium in the blood (hyperkalemia).

Q: What is the difference between Angizaar-H and just taking Angizaar?

Angizaar-H is a fixed-dose combination product that contains both losartan and a diuretic (hydrochlorothiazide). The name 'Angizaar' typically refers to the product that contains only the single ingredient, losartan (monotherapy). The combination product is often prescribed when one medicine alone is not sufficient to control blood pressure.

Q: What are the most common reasons a doctor might prescribe Angizaar-H?

Official indications describe the medicine’s use for the management of high blood pressure (hypertension) when the use of a combination product is considered appropriate. Clinical guidelines support this fixed-dose combination to enhance treatment effectiveness.

Q: Is Angizaar-H considered safe for older adults?

The safety profile for this medicine is described in official documents for the adult population as a whole. While some clinical studies have explored the effects in different age groups, official product information does not specify a separate safety classification for older adults.

Q: How does Angizaar-H affect kidney function over time?

Official warnings describe a risk of renal function deterioration when the medicine is used alongside certain other drugs, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The medicine is contraindicated (is not to be used) in people with severe renal impairment (very poor kidney function).

Q: Can I take Angizaar-H if I have diabetes?

The medicine is contraindicated (is not to be used) for use with a drug called aliskiren in patients who also have diabetes or moderate-to-severe kidney impairment. This restriction is due to risks associated with the dual blockade of the Renin-Angiotensin System. There are no general restrictions cited for diabetes alone.

Q: Are there any long-term health risks associated with taking Angizaar-H?

Regulatory documents note that long-term, high cumulative exposure to the hydrochlorothiazide component is associated with an increased risk of non-melanoma skin cancer. The need for long-term use may involve continuous monitoring of organ systems.

Q: Can Angizaar-H affect my potassium levels?

Yes, the losartan component may cause potassium levels to rise, while the hydrochlorothiazide component may cause them to fall. Due to this potential effect on electrolyte balance, monitoring of serum electrolyte levels is generally advised by official documents.

Q: Does Angizaar-H cause increased urination?

Yes, the hydrochlorothiazide component is a diuretic, meaning it promotes the removal of fluid. This ingredient works by increasing the excretion of salt and water by the kidneys, which leads to a reduction of fluid volume and resulting in increased urine output.

Q: Is the low blood pressure feeling temporary when starting this medication?

Official warnings note that hypotension (low blood pressure) may be more pronounced at the start of treatment. This indicates that the effect may lessen or stabilize as the patient’s body adjusts to the medication, although low blood pressure is a known side effect.

Q: What type of monitoring is required when taking Angizaar-H?

Official documents advise that monitoring of serum electrolyte levels (like potassium) and renal function (kidney function) is performed at regular intervals. Monitoring blood pressure is also a continuous requirement for managing hypertension.

Q: Can Angizaar-H cause changes in mood or anxiety?

While specific changes in mood or anxiety are generally not cited as common side effects, regulatory documents do list adverse reactions that affect the nervous system. For example, sleep disturbances are classified as an uncommon effect.

Q: What is Angizaar-H used for besides high blood pressure?

According to official documents, the Losartan/HCTZ combination product is only approved for the treatment of high blood pressure (hypertension). The medicine is not officially indicated for the treatment of any other conditions.

Q: How quickly should Angizaar-H start working to lower blood pressure?

Official documents indicate that the effect of the losartan component has an onset that builds up over time. The maximum blood pressure reduction is typically noted within three to six weeks after beginning the therapy.

Q: Does Angizaar-H cause weight gain or weight loss?

The diuretic component (hydrochlorothiazide) is known to cause a reduction in fluid volume, which may be associated with slight, temporary changes in weight. However, significant weight gain or loss is not consistently cited as a common adverse reaction in regulatory documents.

Q: How long does the effect of one dose of Angizaar-H typically last?

Official documents state that the medicine is administered once daily. This dosing regimen is established to provide a sustained effect and ensure 24-hour control over blood pressure.

Q: Can Angizaar-H be used to prevent heart problems, or is it only for treatment?

The medicine is officially approved for the treatment of high blood pressure. While treating hypertension is an important step in reducing the risk of cardiovascular events, regulatory documents classify the medicine's use as treatment of an existing condition.

Q: Can Angizaar-H be split in half if the tablet is scored?

The official instructions for administration generally state that the tablet should be swallowed whole. Unless the manufacturer’s directions explicitly authorize splitting, the medicine is intended to be taken as a complete unit to ensure the correct dosage is delivered.

Q: Can taking Angizaar-H cause muscle cramps?

Specific muscle cramps are not consistently listed as a common adverse effect. However, the medicine is known to affect electrolyte balance in the body, and imbalances in key electrolytes like potassium are known to sometimes be associated with muscle cramping.

Q: Are there restrictions on driving or operating machinery while taking Angizaar-H?

Official documents include a cautionary note that, due to potential adverse effects like dizziness or fatigue, the medicine may affect the ability to drive or operate heavy machinery.

Q: Can Angizaar-H increase my sensitivity to the sun?

Official documents list photosensitivity reactions as an adverse effect associated with the hydrochlorothiazide component. This means the medicine may increase the skin's sensitivity to sunlight.

Q: Is Angizaar-H a branded or a generic drug name?

Angizaar-H is a trade name (branded name) for the combination of losartan potassium and hydrochlorothiazide. These active ingredients are also available under other branded names and as generic drug products.

Advertisements

How should Angizaar-H be stored and disposed of?

Official Storage and Disposal Requirements

Angizaar-H (losartan potassium and hydrochlorothiazide) must be stored and handled according to regulatory standards to maintain its effectiveness.


Storage Conditions

Item Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), allowing excursions up to 30 C.
Protection Keep the tablets protected from light and moisture in a dry place.
Container Must remain in the original container, which should be kept tightly closed.
Safety Store the medicine out of the reach of children.

Disposal Instructions

Unused or expired Angizaar-H must be discarded according to local regulations. Regulatory documents explicitly state that the product should not be flushed down the toilet or disposed of in wastewater or household garbage to protect the environment. Consult local authorities or a pharmacist for medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angizaar-H found in:

A-Z Index: